12 Dec 2019 --- Biotechnology company PanTheryx’s bovine colostrum has received GRAS (Generally Recognized As Safe) status from the US Food and Drug Administration (FDA) after being reviewed by an independent expert panel of scientists. This opens opportunities in expanding the ingredient’s use into new applications for the food and beverage industry globally, the company says. PanTheryx also notes it is committed to realizing the potential of bovine colostrum-based therapies to address a wide range of health conditions. The launch is a significant step in this direction as well and further affirms immunoglobulins’ potential in digestive health.
